We are live on ! Find out more
NVS icon

Novartis

815 hedge funds and large institutions have $19.8B invested in Novartis in 2013 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 286 increasing their positions, 285 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more first-time investments, than exits

New positions opened: 107 | Existing positions closed: 41

36% more call options, than puts

Call options by funds: $182M | Put options by funds: $134M

7% more funds holding

Funds holding: 761815 (+54)

6% more capital invested

Capital invested by funds: $18.7B → $19.8B (+$1.11B)

0% more repeat investments, than reductions

Existing positions increased: 286 | Existing positions reduced: 285

0.09% more ownership

Funds ownership: 9.91%9.99% (+0.09%)

5% less funds holding in top 10

Funds holding in top 10: 5552 (-3)

Holders
815
Holders Change
+54
Holders Change %
+7.1%
% of All Funds
23.65%
Holding in Top 10
52
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-5.45%
% of All Funds
1.51%
New
107
Increased
286
Reduced
285
Closed
41
Calls
$182M
Puts
$134M
Net Calls
+$48M
Net Calls Change
+$25.5M

NVS Hedge Fund Activity: Q4 2013 in Review

815 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2013, worth a combined $19.8B — up 5.9% from $18.7B a quarter earlier.

Buyers outnumbered sellers: 107 funds opened new NVS positions and 41 closed out — a net gain of 66 holders — while 286 added to existing stakes and 285 trimmed.

The largest buyer was EARNEST Partners, opening a new position worth an estimated $179M. The largest seller was Neuberger Berman Group, cutting an estimated $137M.

  • 815 institutional investors held Novartis (NVS) as of Q4 2013, up from 761 in Q3 2013.
  • Funds reported $19.8B of Novartis stock for Q4 2013, up 5.9% quarter-over-quarter.
  • 107 funds opened new Novartis positions in Q4 2013 and 41 closed out, a net change of +66 holders.
  • The largest Novartis buyer in Q4 2013 was EARNEST Partners, an estimated $179M added.
  • The largest Novartis seller in Q4 2013 was Neuberger Berman Group, an estimated $137M sold.

Based on aggregated 13F filings for Q4 2013.